X
Xsensio
Developing a miniaturized sensing platform that can be used to continuously monitor proteins and hormones at the surface of the skin
About Xsensio
Xsensio is a Swiss medtech company developing Lab-on-Skin continuous biosensing wearables that measure biochemical markers such as electrolytes, metabolites, hormones and proteins in sweat at the skin surface with near blood-test precision for clinical and wellness monitoring. The miniaturised sensing platform aims to move intermittent lab assays toward real-time, continuous biochemical insight; in March 2026 the company also announced a long-term collaboration with Texas Instruments on clinical deployment. In March 2026 Xsensio closed an oversubscribed $7 million Series A led by WI Harper, with Privilège Ventures, the European Innovation Council and undisclosed private investors from the US, Europe and Asia, to accelerate clinical deployment of its continuous biosensing technology. Sources: PR Newswire / WI Harper Mar 2026; company.
Source: Dealroom company dataAt a glance
- Founded
- 2017
- Headquarters
- Lausanne, Switzerland
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Venture Kick
MassChallenge
European Innovation Council
Series A3 investors entered at this stage
EIC Fund
Privilège Ventures
WI Harper Group
Series B and later1 investor entered at this stage
Fondation FIT
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Xsensio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Xsensio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.